Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α

被引：73

作者：

Schmidt, M

Hochhaus, A

Nitsche, A

Hehlmann, R

Neubauer, A ^{[1
]}

机构：

[1] Klinikum Phillipps Univ Marburg, Zentrum Innere Med, Abt Hamatol Onkol Immunol, D-35043 Marburg, Germany

[2] Univ Heidelberg, Klinikum Mannheim, Med Klin 3, Heidelberg, Germany

[3] Humboldt Univ, Charite Campus Virchow Klinikum, Klin Innere Med Ms Hamatol & Onkol, Berlin, Germany

来源：

BLOOD | 2001年 / 97卷 / 11期

关键词：

D O I：

10.1182/blood.V97.11.3648

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor (IRF) family, has a potential role in chronic myeloid leukemia (CML). Deletion of ICSBP gene in mice leads to a CML-like syndrome and samples from CML patients exhibited impaired ICSBP expression. The present study found that ICSBP expression correlated with risk features determined by Sokal score in untreated CML (P = .007 for high versus low risk). In addition, analyzing ICSBP expression during interferon-alpha (IFN-alpha) therapy in "good" (n = 27) versus "poor" (n = 15) cytogenetic responders, high ICSBP levels were only observed in "good" responders (P = .0002). Together, these data suggest that ICSBP levels are related to initial presentation of CML and the therapeutic response of CML to IFN-alpha, indicating an important role of ICSBP in CML.

引用

页码：3648 / 3650

页数：3

共 21 条

[11]

Nelson N, 1996, J IMMUNOL, V156, P3711

[12]

Nitsche A, 1999, CLIN CHEM, V45, P1932

[13]

Petska S, 1987, ANNU REV BIOCHEM, V56, P727

[14] Chronic myeloid leukemia [J].